Eledon Pharmaceuticals, Inc. — fact timeline

Eledon Pharmaceuticals, Inc.: Increased number of authorized shares of common stock from 300,000,000 to 450,000,000 (effective 2026-06-18).

“the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Authorized Share Increase Amendment”) to the Company’s Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) to amend the Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 shares.”

Eledon Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for year ending December 31, 2026 at the 2026-06-18 meeting.

“The results of the stockholders’ vote with respect to the ratification were as follows: For Against Abstain Broker Non-Vote 56,010,539 252,240 76,099 0”

Eledon Pharmaceuticals, Inc. shareholders approved Approval of amendment to Certificate of Incorporation to increase authorized shares of common stock from 300,000,000 to 450,000,000 shares at the 2026-06-18 meeting.

“The results of the stockholders’ vote with respect to the approved amendment were as follows: For Against Abstain Broker Non-Vote 52,305,057 3,739,735 294,086 0”

Eledon Pharmaceuticals, Inc. shareholders approved Election of Class III Directors at the 2026-06-18 meeting.

“The results of the stockholders’ vote with respect to the election of the Class III Directors were as follows: Nominee Term Expiring For Withhold Broker Non-Vote David-Alexandre C. Gros, M.D. 2029 36,633,821 426,888 19,278,169 Jan Hillson, M.D. 2029 33,081,275 3,979,434 19,278,169 James Robinson 2029 30,916,807 6,143,902 19,278,169”

Eledon Pharmaceuticals, Inc. reported first quarter 2026 results: net income Net loss for the first quarter of 2026 was $39.0 million, or $0.33 per basic common share, EPS $0.33 per basic common share.

“Net loss for the first quarter of 2026 was $39.0 million, or $0.33 per basic common share”

Eledon Pharmaceuticals, Inc. reported the quarter and year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025 was $45.6 million, or $0.52 per basic share of common stock, EPS $0.52 per basic share of common stock.

“On March 19, 2026, Eledon Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025.”

Eledon Pharmaceuticals, Inc. issued pre-funded warrant to purchase up to 4,203,764 shares of Common Stock of warrant to Coastlands Capital Partners LP.

“the Holder agreed to exchange 4,203,764 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for a pre-funded warrant to purchase up to 4,203,764 shares of Common Stock (the “Exchange Warrant” and such exchange of Common Stock for the Exchange Warrant is referred to herein as the “Exchange”).”

Eledon Pharmaceuticals, Inc.: Extended exculpation protection to officers to the fullest extent permitted by Delaware law.

“a Certificate of Amendment (the “Officer Exculpation Amendment”) to amend the Certificate of Incorporation to extend exculpation protection to officers, to the fullest extent permitted by Delaware law”

Eledon Pharmaceuticals, Inc.: Increased authorized shares of common stock from 200,000,000 to 300,000,000.

“the Company filed the following with the Secretary of State of the State of Delaware: • a Certificate of Amendment (the “Authorized Share Increase Amendment”) to the Company’s Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) to amend the Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000 shares”

Eledon Pharmaceuticals, Inc. engaged Deloitte & Touche LLP as its auditor.

“On April 1, 2025, the Audit Committee approved the engagement of Deloitte & Touche LLP”

Eledon Pharmaceuticals, Inc. dismissed Crowe LLP as its auditor.

“-K, which inadvertently also referenced Crowe LLP with respect to matters related to the Company’s fiscal year ended December 31, 2023. The Company has not made any other changes to the Original 8-K. Item 4.01 Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm. The Audit Committee of the Board of Directors (the “Audit Committee”) of the Company approved the dismissal of Crowe LLP (“Crowe”) as the Company’s independent registered public accounting firm and dismissed Crowe on April 1, 2025. Crowe served as the Company’s independent registered public accounting firm from July 10, 2024 to April 1, 2025.”

Eledon Pharmaceuticals, Inc. engaged Deloitte & Touche LLP as its auditor.

“On April 1, 2025, the Audit Committee approved the engagement of Deloitte & Touche LLP (“Deloitte”) as its new independent registered public accounting firm for the Company’s fiscal year ending December 31, 2025 and related interim periods.”

Eledon Pharmaceuticals, Inc. dismissed Crowe LLP as its auditor.

“The Audit Committee of the Board of Directors (the “Audit Committee”) of Eledon Pharmaceuticals, Inc. (the “Company”) approved the dismissal of Crowe LLP (“Crowe”) as the Company’s independent registered public accounting firm and dismissed Crowe on April 1, 2025.”

Eledon Pharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: net income net loss of $10.3 million, EPS $0.34 per share.

“The Company reported a net loss of $10.3 million, or $0.34 per share, for the three months ended March 31, 2024, compared to a net loss of $10.8 million, or $0.75 per share, for the same period in 2023.”

Eledon Pharmaceuticals, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-05-06).

“In connection with the Private Placement, the Company entered into a registration rights agreement, dated May 6, 2024 (the “Registration Rights Agreement”), with the Purchasers, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 to register for resale the Shares and the shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants within 20 calendar days, and (ii) use its reasonable best efforts to have the registration statement declared effective promptly after filing, and in any event no later than 60 days after the date of the Securities Purchase Agreement (or 90 days after the date of the Securities Purchase Agreement if the registration statement is reviewed by the SEC).”

Eledon Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors (the "Purchasers") valued at approximately $50 million (effective 2024-05-06).

“On May 6, 2024, Eledon Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) an aggregate of 13,110,484 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) at a price of $2.37 per share, and pre-funded warrants (the “Pre-Funded Warrants”) at a price of $2.369 per underlying share, which are exercisable to purchase 7,989,516 shares of Common Stock at an exercise price of $0.001 per share.”

Eledon Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income net loss of $40.3 million, or $1.64 per share, EPS $1.64 per share.

“The Company reported a net loss of $40.3 million, or $1.64 per share, for the year ended December 31, 2023, compared to a net loss of $88.0 million, or $6.16 per share, in 2022.”

Eledon Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income net loss of $9.6 million, or $0.32 per share, EPS $0.32 per share.

“The Company reported a net loss of $9.6 million, or $0.32 per share, for the three months ended December 31, 2023, compared to a net loss of $58.4 million, or $4.09 per share, for the same period in 2022.”

Eledon Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: net income net loss of $10.3 million, or $0.35 per share, EPS $0.35 per share.

“The company reported a net loss of $10.3 million, or $0.35 per share, for the three months ended September 30, 2023, compared to a net loss of $10.5 million, or $0.73 per share, for the same period in 2022.”

Allan Douglas Kirk was appointed as Director at Eledon Pharmaceuticals, Inc..

“On September 29, 2023, Allan Douglas Kirk, MD, PhD, FACS, was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”), effective October 2, 2023.”

James Robinson was appointed as director at Eledon Pharmaceuticals, Inc..

“On September 11, 2023, James Robinson was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”), effective October 1, 2023.”

Eledon Pharmaceuticals, Inc. reported second quarter results: net income net loss of $9.6 million, or $0.40 per share, EPS $0.40 per share.

“The company reported a net loss of $9.6 million, or $0.40 per share, for the three months ended June 30, 2023”

Eledon Pharmaceuticals, Inc. shareholders approved Ratification of KMJ Corbin & Company LLP as independent registered public accounting firm at the 2023-06-21 meeting.

“Proposal 4: The stockholders of the Company ratified the appointment of KMJ Corbin & Company LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. The results of the stockholders' vote with respect to the ratification were as follows: For Against Abstain 9,624,236 187,115 4,604”

Eledon Pharmaceuticals, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-21 meeting.

“Proposal 3: The stockholders of the Company approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the 2023 definitive proxy statement on Schedule 14A, as follows: For Against Abstain Broker Non-Vote 7,051,556 234,105 257,656 2,272,638”

Eledon Pharmaceuticals, Inc. shareholders approved Approval of amendment to the 2020 Incentive Plan to increase shares available by 9,600,000 at the 2023-06-21 meeting.

“Proposal 2: The stockholders of the Company approved an amendment to the Company's 2020 Incentive Plan, increasing the aggregate number of shares available for issuance by 9,600,000 shares.”

Eledon Pharmaceuticals, Inc. shareholders approved Election of Class III Directors at the 2023-06-21 meeting.

“Proposal 1: The stockholders of the Company elected each of David-Alexandre C. Gros, M.D. and Jan Hillson, M.D. as Class III Directors for a three-year term ending at the Annual Meeting of Stockholders to be held in 2026 and until each of their successors has been duly elected and qualified, or until their earlier death, resignation or removal.”

Eledon Pharmaceuticals, Inc. reported three months ended March 31, 2023 results: net income net loss of $10.8 million, or $0.75 per share, EPS $0.75 per share.

“The Company reported a net loss of $10.8 million, or $0.75 per share, for the three months ended March 31, 2023, compared to a net loss of $9.9 million, or $0.69 per share, for the same period in 2022.”

Eledon Pharmaceuticals, Inc. entered into Registration Rights Agreement with Institutional and accredited investors valued at Company to file registration statement within 20 days, use best efforts to have it declared effectiv (effective 2023-04-28).

“In connection with the Private Placement, the Company entered into a registration rights agreement, dated April 28, 2023 (the “Registration Rights Agreement”), with the Purchasers, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 to register for resale the Shares and the shares of Common Stock issuable upon the exercise of the Warrants within 20 calendar days, and (ii) use its reasonable best efforts to have the registration statement declared effective promptly after filing, and in any event no later than 60 days after the date of the Securities Purchase Agreement (or 90 days after the date of the Securities Purchase Agreement if the registration statement is reviewed by the SEC).”

Gary A. Lyons departed as Director at Eledon Pharmaceuticals, Inc..

“On April 26, 2023, Gary A. Lyons notified the Company that he is retiring from the Board of Directors of the Company at the end of his term and will not be standing for election at the Company’s 2023 annual meeting of stockholders.”

Eledon Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: net income net loss of $88.0 million, or $6.16 per share.

“The Company reported a net loss of $88.0 million, or $6.16 per share, for the year ended December 31, 2022, compared to a net loss of $34.5 million, or $2.33 per share, in 2021.”

Eledon Pharmaceuticals, Inc. reported the four months ended December 31, 2022 results: net income net loss of $58.4 million, or $4.09 per share.

“The Company reported a net loss of $58.4 million, or $4.09 per share, for the three months ended December 31, 2022, compared to a net loss of $8.8 million, or $0.59 per share, for the same period in 2021.”

Eledon Pharmaceuticals, Inc. reported the three months ended September 30, 2022 results: net income $10.5 million, EPS $0.73 per share.

“The company reported a net loss of $10.5 million, or $0.73 per share, for the three months ended September 30, 2022”

Paul Little was appointed as Principal Accounting Officer at Eledon Pharmaceuticals, Inc..

“the Company’s Board of Directors appointed Paul Little as the Company’s Principal Accounting Officer, effective as of July 31, 2021.”

Jon Kuwahara resigned as Senior Vice President, Finance & Administration and Principal Accounting Officer at Eledon Pharmaceuticals, Inc..

“Effective July 31, 2021, Jon Kuwahara resigned as the Senior Vice President, Finance & Administration and Principal Accounting Officer of Eledon Pharmaceuticals, Inc. (the “Company”).”

Jan Hillson, M.D. was appointed as Director at Eledon Pharmaceuticals, Inc..

“On July 1, 2021, Jan Hillson, M.D. was appointed to the board of directors (the “Board”) of Eledon Pharmaceuticals, Inc., (“Eledon”).”